31 TIP TROPION-Breast03: Datopotamab Deruxtecan (Dato-DXd) ± Durvalumab vs Investigator’s Choice of Therapy (ICT) for Triple-Negative Breast Cancer (TNBC) with Residual Disease Following Neoadjuvant TherapyByAditya Bardia, MD, MPH,Lajos Pusztai, MD, DPhil,Kathy S. Albain, MD,Kevin Kalinsky, MD, MS,Dawn Herman,William Barlow,Claudine Isaacs, MD,Micah Maxwell,Nadia Harbeck, MD, PhD,Priyanka Sharma, MDApril 27th 2023